{
    "nct_id": "NCT05836324",
    "official_title": "A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* ≥18 years old\n* Histologically or cytologically confirmed advanced or metastatic malignancies as defined in the protocol.\n* Participants must have experienced disease progression after treatment with available therapies, including anti-PD-(L)1 or anti-CTLA4 therapy if applicable, that are known to confer clinical benefit, or who are intolerant to, or ineligible for standard treatment. Prior anti-PD-(L)1 therapy should not have been discontinued because of intolerance.\n* ECOG performance status score of 0 or 1.\n* Willingness to undergo pre- and on-treatment tumor biopsy (core or excisional). Biopsies are mandatory for Part 1b cohorts only.\n* Presence of measurable disease according to RECIST v1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years\n* Not recovered to ≤ Grade 1 or baseline from residual toxicities of prior therapy\n* Has active autoimmune disease requiring systemic immunosuppression with corticosteroids Brain or CNS metastases untreated or that have progressed\n* History of organ transplant, including allogeneic stem cell transplantation.\n* Received more than 4 prior anticancer regimen(s) for advanced or metastatic disease.\n* History of clinically significant or uncontrolled cardiac disease\n* Active HBV (or at risk of activation), active HCV, or HIV positive\n* Is on chronic systemic steroids (> 10 mg/day of prednisone or equivalent).\n* Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment\n* Participants that have been initiated on or had modifications in anticoagulation therapies within the last 3 months prior to first dose of treatment.\n* Significant concurrent, uncontrolled medical condition, eg:\n\n  * Cardiovascular: Participants with known vasculitis, aneurisms, and other vascular malformations of clinical significance\n* Participants with adequate laboratory values within the protocol defined ranges.",
    "miscellaneous_criteria": ""
}